Market View

The U.S. market is in a Confirmed Uptrend. Indices, led by the Nasdaq, rallied back into all-timehighs. Alt-hough the distribution day count increased to six on the Nasdaq and fiveon the S&P, price action across leader-ship ideas remains constructive. We will become more cautiousif distribution remains elevated as indi-ces/leading stocks fall below key support levels.

Stocks on our U.S. Focus List—Current SentimentOur USFL of 73 ideas (no net change)gained 1.6% on averagethis week, outperforming the S&P 500(-0.1%) and the Nasdaq (0.5%).

By Sector

Technology ideas on the U.S Focus List continue to outperform. EXTRand WBrose over 10% after reporting good results last week. EXTRis buyable. ALRMregained its 100-DMA on strong volume but remains below its 50-DMA and is poised to consolidate. Consumer Staple outperformed, led by heavy accumulation in BUFFand MNST. Within Financial, payment processors including PYPLcontinue totrend higher.

Global Health Care Sector

U.S. Health Care Sector
The Health Care Sector has slowed on a relative basis over the past two months and is now declining on an absolute basis over the last three weeks. The sector is now trading below its 50- and 100-DMAs, largely due to a recent sell-off in the Biotech and Ethical Drug industry groups, which make up the bulk of the sector. We are now looking for the lower channel line to hold before support along the 200-DMA. Though we have become cautious on the Biotechs due to multiple bellwethers breaking individual technical support levels, other industry groups within Health Care remain healthy, including Products, Equipment, and Managed Care. Also, long-term lagging industry groups (Hospitals and Wholesalers) remain weak and should continue to be avoided. Currently, S&P 500 Health Care companies are trading exactly in-line with the S&P 500. Both are trading at a median of 18x 2018 EPS with consensus 2018 median EPS growth of 10% y/y.